PHARMACEUTICAL FORMULATIONS OF AMYLOID INHIBITING COMPOUNDS

• US 20090182056A1
• Filed: 01/30/2009
• Published: 07/16/2009
• Est. Priority Date: 06/23/2003
• Status: Active Grant

• Current Assignee: BELLUS Health, Inc. (GSK plc)
• Original Assignee: BHI Limited Partnership
• Inventors: LAURIN, Julie, Garceau, Denis
• Granted Patent: US 8,835,500 B2
• Time in Patent Office: Days
• US Class Current: 514/578
• CPC Class Codes: A61K 31/185 Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids hydroxamic acids A61K31/16; peroxy acids A61K31/327
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/2846 Poly(meth)acrylates
• CPC Class Codes: A61K 9/2886 having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer of the type active core-drug layer-inactive layer A61K9/209
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/04 Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Therapeutic formulations and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Therapeutic formulations and methods for preventing or treating amyloidosis and/or amyloid-related disease are also described.

Claims

1-16. -16. (canceled)

17. A method for treating a viral infection in a subject comprising orally administering to the subject a therapeutic formulation comprising an effective amount of a therapeutic formulation comprising the therapeutic compound, 3-amino-1-propanosulfonic acid or a pharmaceutically acceptable salt thereof, formulated to significantly reduce or prevent gastrointestinal intolerance.

18. The method of claim 17, wherein the viral infection is HSV.

19. A method for treating a viral infection in a subject comprising orally administering to the subject a therapeutic formulation comprising an effective amount of a therapeutic formulation comprising the therapeutic compound, 3-amino-1-propanosulfonic acid or a pharmaceutically acceptable salt thereof, formulated to significantly reduce or prevent gastrointestinal intolerance in comparison to such intolerance which occurs when said compound is orally administered in immediate release form.

20. A method for treating a viral infection in a subject comprising orally administering to the subject a therapeutic formulation comprising an effective amount of a therapeutic formulation comprising the therapeutic compound, 3-amino-1-propanosulfonic acid or a pharmaceutically acceptable salt thereof, said formulation, when administered to such subjects, being effective to relieve side effects of nausea and/or vomiting such that such side effects are observed in 35% or less of such subjects.